10-Q · August 7, 2026
Maravai reported Q2 2026 revenue of $51.442 million and diluted EPS of $(0.02), with revenue lower than the unusually strong $66 million Q1 but higher than approximately $47 million in the prior-year quarter. Liquidity…
Earnings analysis · 10-Q
MRVI earnings analysis
Filed November 5, 2026 · Our reading of the company's report
The latest report
Maravai reported Q3 revenue of $45.851 million, above consensus by 5.5%, with 11.8% TriLink growth and 7.5% Cygnus growth. Adjusted EBITDA improved by $16.587 million to $5.820 million, but the provided 10-Q excerpt…
Read full summary
Maravai reported Q3 revenue of $45.851 million, above consensus by 5.5%, with 11.8% TriLink growth and 7.5% Cygnus growth. Adjusted EBITDA improved by $16.587 million to $5.820 million, but the provided 10-Q excerpt does not contain the financial statement tables needed to assess current gross margin, operating margin, or free cash flow. Liquidity was supported by $73.0 million of cash, although $150.0 million of variable-rate Term Loan debt leaves the company exposed to higher interest expense.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.03
- Segment
- TriLink: revenue grew 11.8% year over year.
- Segment
- Cygnus: revenue grew 7.5% year over year.
What stood out
-
Revenue Beat and Year-over-Year Growth
Q3 revenue was $45.851 million, exceeding the $43.449 million consensus estimate by approximately $2.402 million, or 5.5%. Revenue increased 10.1% versus Q3 2025 revenue of approximately $42 million.
-
Both Segments Delivered Growth
Both operating segments grew: TriLink revenue increased 11.8% year over year and Cygnus revenue increased 7.5% year over year.
-
Adjusted EBITDA Improved Materially
Adjusted EBITDA improved to $5.820 million from a $10.767 million loss in the prior-year quarter, an improvement of $16.587 million.
-
Cash and Revolver Capacity
The company held $73.0 million of cash and cash equivalents as of September 30, 2026, while maintaining $150.0 million of Term Loan borrowings and no borrowings under the revolving facility.
-
Disclosure Controls Remained Effective
Management stated that disclosure controls and procedures were effective at a reasonable-assurance level as of September 30, 2026, and reported no material changes in internal control during the quarter.
What to watch
-
Variable-Rate Debt Exposure
Variable-rate debt creates cash-flow sensitivity: the company had $150.0 million of Term Loan borrowings at September 30, 2026, and a hypothetical 100-basis-point rate increase would have raised quarterly interest expense by approximately $0.4 million.
-
International and Currency Exposure
International sales represented 36.9% of Q3 revenue and 41.8% of nine-month revenue. Although substantially all sales are denominated in U.S. dollars, the company has no foreign-currency hedging arrangements and states that expanding international operations could increase currency risk.
-
No Formal Risk-Factor Update
The 10-Q states that there were no material changes to the risk factors disclosed in the 2025 Form 10-K. Litigation remains an ongoing potential cost even though the company reported no currently pending proceedings expected to have a material adverse effect.
Management's outlook
The provided 10-Q excerpt does not include quantitative guidance. The prior 8-K reported full-year 2026 revenue guidance of $212.0 million-$216.0 million and adjusted EBITDA guidance of $40.0 million-$42.0 million, both raised from prior ranges.
Earlier filings 4
10-Q · May 8, 2026
Maravai LifeSciences reported strong results for Q1 2026 with a revenue of $65.8 million, exceeding expectations of $53.3 million, and showing a significant increase from $46.9 million in Q1 2025. The company achieved a…
10-K · February 26, 2026
Maravai (MRVI) operates two reportable segments — TriLink (64% of 2025 revenue) and Cygnus (36% of 2025 revenue) — centered on nucleic acid products and biologics safety testing. The company shows a meaningful IP…
10-Q · November 7, 2025
Maravai LifeSciences reported a significant decline in Q3 2025 revenue, which dropped to $41.63 million from $69.03 million year-over-year, reflecting a 39.6% decrease. Net loss attributed to shareholders was $25.56…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.